Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Cycle ; 8(18): 3025-38, 2009 Sep 15.
Article in English | MEDLINE | ID: mdl-19713760

ABSTRACT

Microtubule-targeting cancer therapies interfere with mitotic spindle dynamics and block cells in mitosis by activating the mitotic checkpoint. Cells arrested in mitosis may remain arrested for extended periods of time or undergo mitotic slippage and enter interphase without having separated their chromosomes. How extended mitotic arrest and mitotic slippage contribute to subsequent cell death or survival is incompletely understood. To address this question, automated fluorescence microscopy assays were designed and used to screen chemical libraries for modulators of mitotic slippage. Chlorpromazine and triflupromazine were identified as drugs that inhibit mitotic slippage and SU6656 and geraldol as chemicals that stimulate mitotic slippage. Using the drugs to extend mitotic arrest imposed by low concentrations of paclitaxel led to increased cell survival and proliferation after drug removal. Cells arrested at mitosis with paclitaxel or vinblastine and chemically induced to undergo mitotic slippage underwent several rounds of DNA replication without cell division and exhibited signs of senescence but eventually all died. By contrast, cells arrested at mitosis with the KSP/Eg5 inhibitor S-trityl-L-cysteine and induced to undergo mitotic slippage were able to successfully divide and continued to proliferate after drug removal. These results show that reinforcing mitotic arrest with drugs that inhibit mitotic slippage can lead to increased cell survival and proliferation, while inducing mitotic slippage in cells treated with microtubule-targeting drugs seems to lead to protracted cell death.


Subject(s)
Cell Proliferation/drug effects , Cell Survival/drug effects , Flavones/pharmacology , Mitosis/drug effects , Cell Line, Tumor , Chlorpromazine/pharmacology , Cysteine/analogs & derivatives , Cysteine/pharmacology , Humans , Indoles/pharmacology , Microtubules/drug effects , Paclitaxel/pharmacology , Sulfonamides/pharmacology , Triflupromazine/pharmacology , Vinblastine/pharmacology
2.
BMC Microbiol ; 9: 9, 2009 Jan 14.
Article in English | MEDLINE | ID: mdl-19144191

ABSTRACT

BACKGROUND: Single genome-wide screens for the effect of altered gene dosage on drug sensitivity in the model organism Saccharomyces cerevisiae provide only a partial picture of the mechanism of action of a drug. RESULTS: Using the example of the tumor cell invasion inhibitor dihydromotuporamine C, we show that a more complete picture of drug action can be obtained by combining different chemical genomics approaches--analysis of the sensitivity of rho0 cells lacking mitochondrial DNA, drug-induced haploinsufficiency, suppression of drug sensitivity by gene overexpression and chemical-genetic synthetic lethality screening using strains deleted of nonessential genes. Killing of yeast by this chemical requires a functional mitochondrial electron-transport chain and cytochrome c heme lyase function. However, we find that it does not require genes associated with programmed cell death in yeast. The chemical also inhibits endocytosis and intracellular vesicle trafficking and interferes with vacuolar acidification in yeast and in human cancer cells. These effects can all be ascribed to inhibition of sphingolipid biosynthesis by dihydromotuporamine C. CONCLUSION: Despite their similar conceptual basis, namely altering drug sensitivity by modifying gene dosage, each of the screening approaches provided a distinct set of information that, when integrated, revealed a more complete picture of the mechanism of action of a drug on cells.


Subject(s)
Genomics/methods , Heterocyclic Compounds, 1-Ring/pharmacology , Propylamines/pharmacology , Saccharomyces cerevisiae/drug effects , Sphingolipids/biosynthesis , Anti-Bacterial Agents/pharmacology , Antifungal Agents/pharmacology , Antineoplastic Agents/pharmacology , Cell Death/drug effects , Cell Line, Tumor , Drug Resistance, Fungal/genetics , Gene Dosage , Gene Expression Regulation, Fungal , Genes, Fungal , Humans , Hydrogen-Ion Concentration , Lyases/metabolism , Microbial Sensitivity Tests , Mitochondria/physiology , Saccharomyces cerevisiae/growth & development , Saccharomyces cerevisiae/metabolism , Transport Vesicles/drug effects
3.
Cancer Chemother Pharmacol ; 61(3): 407-13, 2008 Mar.
Article in English | MEDLINE | ID: mdl-17440726

ABSTRACT

G(2) checkpoint inhibitors can force cells arrested in G(2) phase by DNA damage to enter mitosis. In this manner, several G(2) checkpoint inhibitors can enhance killing of cancer cells by ionizing radiation and DNA-damaging chemotherapeutic agents, particularly in cells lacking p53 function. All G(2) checkpoint inhibitors identified to date target protein phosphorylation by inhibiting checkpoint kinases or phosphatases. Using a phenotypic cell-based assay for G(2) checkpoint inhibitors, we have screened a large collection of plant extracts and identified Z-Cryptofolione and Cryptomoscatone D2 as highly efficacious inhibitors of the G(2) checkpoint. These compounds and related pyrones also inhibit nuclear export. Leptomycin B, a potent inhibitor of Crm1-mediated nuclear export, is also a very potent G(2) checkpoint inhibitor. These compounds possess a reactive Michael acceptor site and do not appear promising as a radiosensitizing agents because they are toxic to unirradiated cells at checkpoint inhibitory concentrations. Nevertheless, the results show that inhibition of nuclear export is an alternative to checkpoint kinase inhibition for abrogating the G(2) checkpoint and they should stimulate the search for less toxic nuclear export inhibitors.


Subject(s)
Cell Nucleus/metabolism , Cell Nucleus/radiation effects , Cryptocarya/metabolism , Cryptocarya/radiation effects , G2 Phase/radiation effects , Pyrones/metabolism , Cell Line, Tumor , Enzyme-Linked Immunosorbent Assay , Fatty Acids, Unsaturated/pharmacology , Gamma Rays , Genes, Reporter/genetics , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , HIV Reverse Transcriptase/genetics , HIV Reverse Transcriptase/metabolism , Humans , Karyopherins/physiology , Plant Extracts/pharmacology , Receptors, Cytoplasmic and Nuclear/physiology , Exportin 1 Protein
4.
Mol Cancer Ther ; 4(5): 772-8, 2005 May.
Article in English | MEDLINE | ID: mdl-15897241

ABSTRACT

Strongylophorine-26, a new meroditerpenoid, was recently identified as an inhibitor of cancer cell invasion. This study was undertaken to characterize its mechanism of action. We find that strongylophorine-26 inhibits the motility of MDA-MB-231 breast carcinoma cells on a plastic surface. Upon addition of strongylophorine-26, rapid cell contraction and depolarization occurred, followed by spreading and flattening of the entire cell. Treated cells exhibited increased membrane ruffling throughout and extended lamellipodia in all directions. Strongylophorine-26 induced a decrease in actin stress fibers, a dramatic increase in the size and number of focal adhesions, and the appearance of a dense meshwork of actin filaments around the cell periphery. Strongylophorine-26 caused a transient activation of the small GTPase Rho and treatment with the Rho inhibitor C3 exoenzyme abrogated the anti-invasive activity of strongylophorine-26. These effects are distinct from those of many motility and angiogenesis inhibitors that seem to act by a common mechanism involving the induction of actin stress fibers. This difference in mechanism of action sets strongylophorine-26 apart as an experimental anticancer agent and indicates that pharmacologic inhibition of cell migration may be achieved by mechanisms not involving the stabilization of actin stress fibers.


Subject(s)
Actins/metabolism , Breast Neoplasms/metabolism , Cell Movement/drug effects , Diterpenes/pharmacology , Focal Adhesions/drug effects , Neoplasm Invasiveness/prevention & control , Stress Fibers/drug effects , rho GTP-Binding Proteins/physiology , ADP Ribose Transferases/metabolism , Botulinum Toxins/metabolism , Breast Neoplasms/pathology , Cell Membrane/metabolism , Female , Humans , Pseudopodia/metabolism , Tumor Cells, Cultured
5.
J Nat Prod ; 67(8): 1387-9, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15332859

ABSTRACT

Strongylophorine-26 (1), a new meroditerpenoid that shows activity in an anti-invasion assay, has been isolated from the marine sponge Petrosia (Strongylophora) corticata collected in Papua New Guinea. The structure of 1 was elucidated by analysis of spectroscopic data.


Subject(s)
Antineoplastic Agents/isolation & purification , Diterpenes/isolation & purification , Porifera/chemistry , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Diterpenes/chemistry , Diterpenes/pharmacology , Drug Screening Assays, Antitumor , Humans , Molecular Structure , Nuclear Magnetic Resonance, Biomolecular , Papua New Guinea , Tumor Cells, Cultured
6.
Proc Natl Acad Sci U S A ; 101(13): 4525-30, 2004 Mar 30.
Article in English | MEDLINE | ID: mdl-15070751

ABSTRACT

Methods to systematically test drugs against all possible proteins in a cell are needed to identify the targets underlying their therapeutic action and unwanted effects. Here, we show that a genome-wide drug-induced haploinsufficiency screen by using yeast can reveal drug mode of action in yeast and can be used to predict drug mode of action in human cells. We demonstrate that dihydromotuporamine C, a compound in preclinical development that inhibits angiogenesis and metastasis by an unknown mechanism, targets sphingolipid metabolism. The systematic, unbiased and genome-wide nature of this technique makes it attractive as a general approach to identify cellular pathways affected by drugs.


Subject(s)
Antifungal Agents/pharmacology , Gene Deletion , Genome, Fungal , Saccharomyces cerevisiae/genetics , Sequence Deletion , Animals , Microbial Sensitivity Tests , Ploidies , Saccharomyces cerevisiae/drug effects , Signal Transduction , Sphingolipids/biosynthesis
7.
Cancer Res ; 64(4): 1468-74, 2004 Feb 15.
Article in English | MEDLINE | ID: mdl-14973060

ABSTRACT

The motuporamines are macrocyclic alkaloids that inhibit tumor cell invasion by an, as yet, unknown mechanism. A structure-activity study recently identified dihydromotuporamine C (dhMotC) as a highly active and readily synthesized analogue. Here, we show that dhMotC causes subtle cytoskeletal alterations in highly invasive MDA231 breast tumor cells that include an increase in the thickness and number of cytoplasmic actin stress fibers. Experiments with serum-starved Swiss 3T3 fibroblasts showed that micromolar concentrations of dhMotC that inhibit tumor cell invasion induce the formation of new stress fibers and large focal adhesion complexes that are dispersed around the entire cell periphery. dhMotC treatment of Swiss 3T3 cells also initiates a strong, long-lived activation of the small GTP-binding protein Rho, and it stimulates Rho kinase-dependent sodium-proton exchanger activity. Liposome-mediated cell loading of C3 exoenzyme prevents dhMotC-mediated Rho activation and stress fiber formation in 3T3 cells. C3 exoenzyme loading also reestablishes elongated MDA231 breast tumor cell invasion in the presence of dhMotC. Taken together, these results indicate that the ability to activate Rho is one important determinant of the anti-invasive activity of dhMotC.


Subject(s)
Antineoplastic Agents/pharmacology , Focal Adhesions/drug effects , Neoplasm Invasiveness/prevention & control , Sodium-Hydrogen Exchangers/drug effects , Stress Fibers/drug effects , rho GTP-Binding Proteins/physiology , Alkaloids/pharmacology , Animals , Cell Line, Tumor , Enzyme Activation , Female , Humans , Mice , Sodium/metabolism , Swiss 3T3 Cells
8.
J Org Chem ; 67(1): 245-58, 2002 Jan 11.
Article in English | MEDLINE | ID: mdl-11777468

ABSTRACT

Extracts of the sponge Xestospongia exigua collected in Papua New Guinea were positive in a new assay for anti-invasion activity. Bioassay-guided fractionation led to the identification of the three known motuporamines A (1), B (2), and C (3) along with the new motuporamines D (4), E (5), and F (6) and a mixture of G, H, and I (15). Motuporamines A (1), B (2), and C (3) and the mixture of G, H, and I (15) were responsible for the anti-invasion activity of the crude extract. Motuporamine C (3) has also been found to be anti-angiogenic. A series of analogues of the motuporamines have been synthesized and evaluated for anti-invasive activity. These SAR results revealed that a saturated 15-membered cyclic amine fused to the natural motuporamine diamine side chain (13) represented the optimal structure for anti-invasive activity in this family. Single-crystal X-ray diffraction analysis of one of the analogues 20 showed that in the solid state its 16-membered macrocyclic amine fragment adopted the [4444] quadrangular conformation predicted by calculations to be the lowest energy conformation for the corresponding cycloalkane, cyclohexadecane. These data along with literature X-ray data and conformational analysis for derivatives of azacyclotridecane have been used as precedents for predicting the lowest energy ring conformations of other motuporamines. The SAR data from the natural and synthetic motuporamines have been combined with the conformational analyses to provide an outline of the functionality and shape required for activity in this family of alkaloids and to design a new analogue 49 that showed good anti-invasion activity.


Subject(s)
Alkaloids/chemistry , Antineoplastic Agents/chemistry , Alkaloids/isolation & purification , Angiogenesis Inhibitors/chemistry , Angiogenesis Inhibitors/isolation & purification , Animals , Antineoplastic Agents/isolation & purification , Drug Screening Assays, Antitumor , Humans , Molecular Structure , Neoplasm Metastasis/drug therapy , Neoplasm Metastasis/prevention & control , Nuclear Magnetic Resonance, Biomolecular , Porifera/chemistry , Structure-Activity Relationship , Tumor Cells, Cultured/drug effects , X-Ray Diffraction
SELECTION OF CITATIONS
SEARCH DETAIL
...